Skip to main content

Advertisement

SpringerLink
Log in

A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy

  • ORIGINAL ARTICLE
  • Published:
Modern Rheumatology

Abstract

Infliximab, a chimeric anti-tumor necrosis factor α (TNF-α) monoclonal antibody, has been recognized as significantly improving the course of rheumatoid arthritis (RA); however, a subset of patients shows poor responses. To understand the mechanism underlying such unresponsiveness, I examined the clinical pharmacokinetics (PK) of infliximab, using time–serum concentration profiles obtained from 21 RA patients who had received infliximab therapy in combination with methotrexate (MTX). At week 14 of therapy, 15 cases achieved good or moderate responses in the European League Against Rheumatism (EULAR) criteria, and 3 cases resulted in nonresponders. The others discontinued therapy because of severe adverse effects or aggravation of disease activities. The means of distribution volume and elimination half-life (t 1/2) during the first 2 weeks were 0.05 l/kg and 9.5 days, respectively. Through 14 weeks, most good and moderate responders maintained serum concentrations of more than 1 µg/ml, even immediately before the next infusions. Only 3 cases among good or moderate responders showed undetectable levels of trough serum concentration at week 14. In contrast, the PK profiles of all nonresponders except one showed rapid clearance during therapy. These data support the idea that the rapid clearance of infliximab is the main cause of poor therapeutic responses. I also found that the t 1/2 during the first 2 weeks is inversely correlated to the disease activity scores for 28 joints at the start of treatment, suggesting that TNF-α levels may determine the disease activity of RA. For patients who showed a rapid clearance of infliximab, the increased use of prednisone or MTX was beneficial to achieve sufficient clinical responses. The addition of tacrolimus was effective to improve the clinical outcomes of nonresponders. Thus PK data apparently offer guidance when modified treatment for infliximab-resistant RA patients is being considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. JC Beckham DS Caldwell BL Peterson AM Pippen MS Currie FJ Keefe et al. (1992) ArticleTitleDisease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures J Clin Immunol 12 353–61 Occurrence Handle1430106 Occurrence Handle10.1007/BF00920793 Occurrence Handle1:STN:280:ByyD2MrivFE%3D

    Article  PubMed  CAS  Google Scholar 

  2. CQ Chu M Field M Feldmann RN Maini (1991) ArticleTitleLocalization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis Arthritis Rheum 34 1125–32 Occurrence Handle1930331 Occurrence Handle10.1002/art.1780340908 Occurrence Handle1:STN:280:By2D38bht1c%3D

    Article  PubMed  CAS  Google Scholar 

  3. PE Lipsky DM van der Heijde EW St Clair DE Furst FC Breedveld JR Kalden et al. (2000) ArticleTitleInfliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 343 1594–602 Occurrence Handle11096166 Occurrence Handle10.1056/NEJM200011303432202 Occurrence Handle1:CAS:528:DC%2BD3cXovVeltLk%3D

    Article  PubMed  CAS  Google Scholar 

  4. EW St Clair DM van der Heijde JS Smolen RN Maini JM Bathon P Emery et al. (2004) ArticleTitleCombination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial Arthritis Rheum 50 3432–43 Occurrence Handle15529377 Occurrence Handle10.1002/art.20568 Occurrence Handle1:CAS:528:DC%2BD2cXhtVOqtrvJ

    Article  PubMed  CAS  Google Scholar 

  5. L Klareskog D van der Heijde JP de Jager A Gough J Kalden M Malaise et al. (2004) ArticleTitleTherapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 675–81 Occurrence Handle15001324 Occurrence Handle10.1016/S0140-6736(04)15640-7 Occurrence Handle1:CAS:528:DC%2BD2cXhs12jur4%3D

    Article  PubMed  CAS  Google Scholar 

  6. FC Breedveld MH Weisman AF Kavanaugh SB Cohen K Pavelka R van Vollenhoven et al. (2006) ArticleTitleThe PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 26–37 Occurrence Handle16385520 Occurrence Handle10.1002/art.21519 Occurrence Handle1:CAS:528:DC%2BD28XhsVens74%3D

    Article  PubMed  CAS  Google Scholar 

  7. JJ Gomez-Reino L Carmona (2006) ArticleTitleSwitching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period Arthritis Res Ther 8 R29 Occurrence Handle16507128 Occurrence Handle10.1186/ar1881

    Article  PubMed  Google Scholar 

  8. KE Hansen JP Hildebrand MC Genovese JJ Cush S Patel DA Cooley et al. (2004) ArticleTitleThe efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis J Rheumatol 31 1098–102 Occurrence Handle15170921 Occurrence Handle1:CAS:528:DC%2BD2cXlsFWgtrY%3D

    PubMed  CAS  Google Scholar 

  9. MC Wick S Ernestam S Lindblad J Bratt L Klareskog RF van Vollenhoven (2005) ArticleTitleAdalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital Scand J Rheumatol 34 353–8 Occurrence Handle16234182 Occurrence Handle10.1080/03009740510026887 Occurrence Handle1:CAS:528:DC%2BD2MXht1GhtLzF

    Article  PubMed  CAS  Google Scholar 

  10. JM van den Brande H Braat GR van den Brink HH Versteeg CA Bauer I Hoedemaeker et al. (2003) ArticleTitleInfliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease Gastroenterology 124 1774–85 Occurrence Handle12806611 Occurrence Handle10.1016/S0016-5085(03)00382-2 Occurrence Handle1:CAS:528:DC%2BD3sXlt1yrt7Y%3D

    Article  PubMed  CAS  Google Scholar 

  11. A Di Sabatino R Ciccocioppo B Cinque D Millimaggi R Morera L Ricevuti et al. (2004) ArticleTitleDefective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease Gut 53 70–7 Occurrence Handle14684579 Occurrence Handle10.1136/gut.53.1.70 Occurrence Handle1:CAS:528:DC%2BD2cXptlKqsQ%3D%3D

    Article  PubMed  CAS  Google Scholar 

  12. F Wolfe DJ Hawley (1998) ArticleTitleThe longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients J Rheumatol 25 2108–17 Occurrence Handle9818651 Occurrence Handle1:STN:280:DyaK1M%2Fjtl2lsg%3D%3D

    PubMed  CAS  Google Scholar 

  13. AI Catrina C Trollmo E af Klint M Engstrom J Lampa Y Hermansson et al. (2005) ArticleTitleEvidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report Arthritis Rheum 52 61–72 Occurrence Handle15641091 Occurrence Handle10.1002/art.20764 Occurrence Handle1:CAS:528:DC%2BD2MXht1Kisb4%3D

    Article  PubMed  CAS  Google Scholar 

  14. I Nestorov (2005) ArticleTitleClinical pharmacokinetics of tumor necrosis factor antagonists J Rheumatol Suppl 74 13–8 Occurrence Handle15742459 Occurrence Handle1:CAS:528:DC%2BD2MXivVynsrs%3D

    PubMed  CAS  Google Scholar 

  15. S Mori F Imamura C Kiyofuji K Ito Y Koga I Honda et al. (2006) ArticleTitlePneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody Mod Rheumatol 16 58–62 Occurrence Handle16622728 Occurrence Handle10.1007/s10165-005-0454-2

    Article  PubMed  Google Scholar 

  16. S Mori F Imamura C Kiyofuji M Sugimoto (2006) ArticleTitleDevelopment of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody Mod Rheumatol 16 251–5 Occurrence Handle16906378 Occurrence Handle10.1007/s10165-006-0491-5

    Article  PubMed  Google Scholar 

  17. EW St Clair CL Wagner AA Fasanmade B Wang T Schaible A Kavanaugh et al. (2002) ArticleTitleThe relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 46 1451–9 Occurrence Handle12115174 Occurrence Handle10.1002/art.10302 Occurrence Handle1:CAS:528:DC%2BD38Xltlantbc%3D

    Article  PubMed  CAS  Google Scholar 

  18. ML Prevoo MA van't Hof HH Kuper MA van Leeuwen LB van de Putte PL van Riel (1995) ArticleTitleModified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum 38 44–8 Occurrence Handle7818570 Occurrence Handle10.1002/art.1780380107 Occurrence Handle1:STN:280:ByqC3MfjvFI%3D

    Article  PubMed  CAS  Google Scholar 

  19. N Miyasaka T Takeuchi K Eguchi (2005) ArticleTitleOfficial Japanese guidelines for the use of infliximab for rheumatoid arthritis Mod Rheumatol 15 4–8 Occurrence Handle17028815 Occurrence Handle10.1007/s10165-004-0357-7 Occurrence Handle1:CAS:528:DC%2BD2MXhsV2is7k%3D

    Article  PubMed  CAS  Google Scholar 

  20. FC Arnett SM Edworthy DA Bloch DJ McShane JF Fries NS Cooper et al. (1988) ArticleTitleThe American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315–24 Occurrence Handle3358796 Occurrence Handle10.1002/art.1780310302 Occurrence Handle1:STN:280:BieC1M3nt1Q%3D

    Article  PubMed  CAS  Google Scholar 

  21. DT Felson JJ Anderson M Boers C Bombardier D Furst C Goldsmith et al. (1995) ArticleTitleAmerican College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 727–35 Occurrence Handle7779114 Occurrence Handle10.1002/art.1780380602 Occurrence Handle1:STN:280:ByqB1MfgsFI%3D

    Article  PubMed  CAS  Google Scholar 

  22. RN Maini FC Breedveld JR Kalden JS Smolen D Davis JD Macfarlane et al. (1998) ArticleTitleTherapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 1552–63 Occurrence Handle9751087 Occurrence Handle10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W Occurrence Handle1:CAS:528:DyaK1cXmsVChtbg%3D

    Article  PubMed  CAS  Google Scholar 

  23. AF LoBuglio RH Wheeler J Trang A Haynes K Rogers EB Harvey et al. (1989) ArticleTitleMouse/human chimeric monoclonal antibody in man: kinetics and immune response Proc Natl Acad Sci USA 86 4220–4 Occurrence Handle2726771 Occurrence Handle10.1073/pnas.86.11.4220 Occurrence Handle1:CAS:528:DyaL1MXksFGnsbc%3D

    Article  PubMed  CAS  Google Scholar 

  24. DM Knight H Trinh J Le S Siegel D Shealy M McDonough et al. (1993) ArticleTitleConstruction and initial characterization of a mouse-human chimeric anti-TNF antibody Mol Immunol 30 1443–53 Occurrence Handle8232330 Occurrence Handle10.1016/0161-5890(93)90106-L Occurrence Handle1:CAS:528:DyaK2cXivFSisw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  25. RF van Vollenhoven S Brannemark L Klareskog (2004) ArticleTitleDose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect Ann Rheum Dis 63 426–30 Occurrence Handle15020338 Occurrence Handle10.1136/ard.2003.010967 Occurrence Handle1:CAS:528:DC%2BD2cXjs1ahs7o%3D

    Article  PubMed  CAS  Google Scholar 

  26. CL Wagner A Schantz E Barnathan A Olson MA Mascelli J Ford et al. (2003) ArticleTitleConsequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade Dev Biol (Basel) 112 37–53 Occurrence Handle1:CAS:528:DC%2BD3sXpslGms78%3D

    CAS  Google Scholar 

  27. S Pavy A Constantin T Pham L Gossec JF Maillefert A Cantagrel et al. (2006) ArticleTitleMethotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion Joint Bone Spine 73 388–95 Occurrence Handle16626993 Occurrence Handle10.1016/j.jbspin.2006.01.007 Occurrence Handle1:CAS:528:DC%2BD28XptVKjtL0%3D

    Article  PubMed  CAS  Google Scholar 

  28. MP Curran CM Perry (2005) ArticleTitleTacrolimus: in patients with rheumatoid arthritis Drugs 65 993–1001 Occurrence Handle15892590 Occurrence Handle10.2165/00003495-200565070-00005 Occurrence Handle1:CAS:528:DC%2BD2MXltlKqsbs%3D

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Clinical Research Center for Rheumatic Disease, National Kumamoto Saishunsou Hospital, 2659 Suya, Kohshi, 861-1196, Japan

    Shunsuke Mori

Authors
  1. Shunsuke Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shunsuke Mori.

About this article

Cite this article

Mori, S. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy. Mod Rheumatol 17, 83–91 (2007). https://doi.org/10.1007/s10165-006-0544-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-006-0544-9

Key words

Search

Navigation